



## EHA2021 abstracts: What's hot in lymphoma and CLL?

To help navigate the exciting content being presented at the EHA2021 Virtual Congress, the Lymphoma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lymphoma and CLL, in 3 categories: new therapies in development, practice-changing therapies, and advances in disease biology.



**Click**  
the abstracts  
to view

## New therapies in development

### CLL

<b>EP638</b>	<a href="#"><u>TG-1701, a selective Bruton tyrosine kinase (BTK) inhibitor, as monotherapy and in combination with ublituximab and umbralisib (U2) in chronic lymphocytic leukemia (CLL) and lymphoma</u></a>
<b>EP643</b>	<a href="#"><u>A phase 1a/b dose escalation study of the mutation agnostic BTK/FLT3 inhibitor luxepatinib (CG-806) in patients with relapsed or refractory B-cell malignancies</u></a>

### Hodgkin lymphoma

<b>S206</b>	<a href="#"><u>Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: three-year outcome of a multicenter, phase 2 study</u></a>
<b>S207</b>	<a href="#"><u>Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study</u></a>

### Indolent and mantle cell NHL

<b>S214</b>	<a href="#"><u>Tolerability and efficacy of the combination of PI3Kδ inhibitor zandelisib (ME-401) and BTK inhibitor zanubrutinib in patients with relapsed or refractory (R/R) B-cell malignancies: initial results</u></a>
-------------	--

### Aggressive NHL

<b>S218</b>	<a href="#"><u>First-in-human study of the EZH1 and EZH2 dual inhibitor valemestostat tosylate (DS-3201B) in patients with relapsed or refractory non-Hodgkin lymphomas</u></a>
<b>S222</b>	<a href="#"><u>Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab with polatuzumab vedotin for relapsed/refractory B-cell non-Hodgkin's lymphoma</u></a>
<b>EP496</b>	<a href="#"><u>FIRST-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab or tafasitamab + lenalidomide in addition to R-CHOP in patients with newly diagnosed DLBCL</u></a>
<b>LB1903</b>	<a href="#"><u>Safety and efficacy of CD37-targeting naratuximab emtansine plus rituximab in diffuse large B-cell lymphoma and other non-Hodgkin's B-cell lymphomas - a phase 2 study</u></a>



## Practice-changing therapies

### CLL

<b>LB1900</b>	<a href="#"><u>First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma</u></a>
<b>LB1902</b>	<a href="#"><u>Fixed-duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (CLB+O) for first-line (1L) chronic lymphocytic leukemia (CLL): primary analysis of the phase 3 GLOW study</u></a>
<b>S145</b>	<a href="#"><u>First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia</u></a>
<b>S146</b>	<a href="#"><u>Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 4-year follow-up analysis of the randomized CLL14 study</u></a>
<b>S147</b>	<a href="#"><u>Primary analysis of the fixed-duration cohort from the phase 2 CAPTIVATE study of first-line ibrutinib + venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma</u></a>
<b>S148</b>	<a href="#"><u>Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: ELEVATE-TN 4-year follow-up</u></a>
<b>S149</b>	<a href="#"><u>MRD-guided or fixed 12 cycles of venetoclax consolidation after venetoclax plus obinutuzumab treatment in first-line FCR unfit patients with CLL: primary endpoint analysis of the HOVON 139/GIVE TRIAL</u></a>

### Hodgkin lymphoma

<b>S205</b>	<a href="#"><u>Brentuximab vedotin with chemotherapy for patients with previously untreated, stage III or IV classical Hodgkin lymphoma: a 5-year update of the phase 3 ECHELON-1 study (NCT01712490)</u></a>
<b>EP765</b>	<a href="#"><u>Modification of escalated BEACOPP with dacarbazine substitution reduces toxicity while maintaining efficacy for the treatment of advanced-stage Hodgkin lymphoma</u></a>



## Practice-changing therapies

### Indolent and mantle cell NHL

<b>S210</b>	<a href="#"><u>Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma: primary analysis of the phase 2 ELARA trial</u></a>
<b>S211</b>	<a href="#"><u>CHRONOS-3: randomized phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma</u></a>
<b>S213</b>	<a href="#"><u>Outcomes in ZUMA-5 with axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma who had the high-risk feature of early progression after first chemoimmunotherapy</u></a>
<b>LB1904</b>	<a href="#"><u>A comparison of clinical outcomes from ZUMA-5 (axicabtagene ciloleucel) and the international SCHOLAR-5 external control cohort in relapsed/refractory follicular lymphoma (R/R FL)</u></a>

### Aggressive NHL

<b>S219</b>	<a href="#"><u>MATRix followed by autologous transplant is associated with excellent survival and neurotolerability in primary CNS lymphoma: results of the IELSG32 trial at a median follow-up of 88 months</u></a>
<b>S224</b>	<a href="#"><u>No difference in overall survival between R-CHOP and R-EPOCH among patients with advanced stage MYC-rearranged, double hit, or triple hit diffuse large B-cell lymphoma</u></a>
<b>EP499</b>	<a href="#"><u>Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: safety profile and anti-tumor activity</u></a>
<b>EP500</b>	<a href="#"><u>Pirtobrutinib (LOXO-305), a next generation, highly selective, non-covalent BTK inhibitor in previously treated MCL, WM and other NHLs: results from the phase 1/2 BRUIN study</u></a>
<b>EP501</b>	<a href="#"><u>Glofitamab step-up dosing (SUD): updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts)</u></a>
<b>EP503</b>	<a href="#"><u>Mosunetuzumab (mosun) monotherapy for elderly/unfit patients (pts) with first-line diffuse large B-cell lymphoma (DLBCL) continues to show promising safety and efficacy with durable complete responses</u></a>



## Advances in disease biology

S142	<a href="#"><u>FOXO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia: novel therapeutic target</u></a>
S143	<a href="#"><u>Clinical impact of recurrent gene mutations in chronic lymphocytic leukemia: a retrospective, multi-center cohort study by ERIC, the European Research Initiative on CLL, in harmony</u></a>
S144	<a href="#"><u>Genetic markers and outcome in front line obinutuzumab plus chlorambucil or venetoclax - updated analysis of the CLL14 trial</u></a>
S225	<a href="#"><u>Circulating tumor DNA sequencing reveals the genomic landscape of Hodgkin lymphoma and facilitates highly sensitive detection of minimal residual disease</u></a>
S228	<a href="#"><u>Blockade of NCAPD3 as a novel therapeutic approach in diffuse large B-cell lymphoma</u></a>
S229	<a href="#"><u>A systems biology approach to DLBCL predicts emergent phenotypes from molecular dysregulation and identifies distinct roles for NF-KB subunits CREL and RELA</u></a>





Follow us on Twitter to keep up to date with the latest from the EHA2021 Virtual Congress!

@lymphomahub  
#EHA2021  
[lymphomahub.com](https://lymphomahub.com)